Navigation Links
Vermillion Reports Fourth Quarter and Full Year 2012 Results
Date:2/20/2013

company's board has formed a succession committee of independent directors to oversee the process of identifying and selecting a permanent CEO. It has also retained a leading executive search firm with experience in CEO transitions to advise the board on potential candidates.

Conference Call and Webcast
Vermillion will hold a conference call to discuss its fourth quarter and full year financial results later today, Wednesday, February 20, 2013 at 4:30 p.m. Eastern time. Vermillion's interim CEO Bruce A. Huebner will host the call, followed by a question and answer period.

Date: Wednesday, February 20, 2013
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-909-4761
International: 1-212-231-2934
Conference ID#: 21648726
Webcast: http://edge.media-server.com/m/p/e247e2q2/lan/en

The conference call will be webcast live and available for replay via the investor section of the company's website at www.vermillion.com.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available approximately two hours after the call through March 6, 2013.

Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21648726

About OVA1
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.(1) In addition, OVA
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Vermillion Reports Second Quarter 2012 Results
6. Vermillion to Present at the 2012 Gateway Conference on September 6
7. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
8. Vermillion Reports Third Quarter 2012 Results
9. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
10. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
11. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 /PRNewswire-iReach/ -- MarketReportsOnline.com ... China Pharmaceutical Guidebook Series (4) 2013 Edition Material ... for Imported Drug Registration: A Guidebook of Registration ... Medicines " to its online database. ... Chinese medicines are always regarded by occidental as ...
(Date:5/22/2013)... and VANCOUVER, British Columbia , May 22, ... a leader in the development of novel therapeutics to target ... trials of its investigational compounds, custirsen and OGX-427, will be ... Annual Meeting of the American Society of Clinical Oncology ... 31 – June 4. Despite the availability ...
(Date:5/21/2013)... BEIJING, May 21, 2013 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China and the parent ... results for the first quarter ended March 31, 2013 ... , Total net revenue, which consists of net revenues ...
Breaking Medicine Technology:China Pharmaceutical Market Guidebook Series (4) 2013 Report 2China Pharmaceutical Market Guidebook Series (4) 2013 Report 3China Pharmaceutical Market Guidebook Series (4) 2013 Report 4China Pharmaceutical Market Guidebook Series (4) 2013 Report 5OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 2OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 3OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 4OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting 5Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13
... of Inflammatory ... ... MOUNTAIN VIEW, Calif., May 13 ChemoCentryx, Inc., today,announced the initiation ... molecule compound designed to specifically,target the CCR1 chemokine receptor which is ...
... Business, DUBLIN, Ohio, May 12 Cardinal ... improve the safety and,productivity of health care, today ... privately held Enturia, Inc., the manufacturer of,infection prevention ... ChloraPrep(R) brand products are used widely in U.S. ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Cardinal Health Completes Enturia Acquisition 2
(Date:5/21/2013)... 2013 The University of Colorado’s Anschutz ... HEALTHY DINING to help Coloradans make healthier choices when ... program is called HEALTHY DINING IN COLORADO. More ... participating in Colorado. Restaurants will offer a selection of ... lean protein, vegetables, fruits, whole grains and unsaturated fats. ...
(Date:5/21/2013)... May 22, 2013 Swimsuit season is almost ... Whisperer ® products has begun with a 35% discount. , ... estrogen. Many women get the dreaded cellulite even if they ... the skin where they have been stored as toxic lymph ... no easy fixes, a specific program that works to dissolve ...
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 22, 2013 ... globally increasing meat production industry value chain. Most of ... the form of injectable, pellets, liquids, and powders. There ... in different quantities and concentrations depending upon the type ... acids, minerals, and vitamins that provide essential nutrition to ...
(Date:5/21/2013)... George Washington (GW) University School of Public ... launch of the Avance Center for the ... SPHHS, the Maryland Multicultural Youth Centers, the ... university-community partnership aims to address public health ... research, mutual capacity building and prevention efforts. ...
(Date:5/21/2013)... Medical Ministry International announced today that it has ... GreatNonprofits , the leading provider of user reviews about nonprofit ... 2013 Nonprofit,” says Samuel Smith, MMI CEO. This does ... and Staff serving in 22 countries around the world. This ... have seen our work first hand and wanted to tell ...
Breaking Medicine News(10 mins):Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 2Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 3Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2
... U.S. organ transplant system often fails to detect or fix ... according to the Los Angeles Times on Sunday. ... are usually kept a secret leaving patients and their families ... ,This nonprofit agency has been given the contract ...
... at the Indian Institute of Technology (IIT), Chennai, have ... them into cells, a// major step towards drug efficacy. ... that comprises a core of one material and a ... of delivering therapeutic molecules into cells and monitoring it ...
... 80% accuracy in prediction of the most effective drug against ... test that examines the// genetic material of a patient’s tumour. ... North Carolina report that this genomic test is useful in ... a particular cancer but also a combination of drugs. ...
... chefs are two to four times bigger than the government's ... contributing to increasing weight of their diners, the chefs believe ... ,These were the findings that were revealed by a ... the Obesity Society. ,A meal at a restaurant ...
... and bad news for women faced with the decision about ... is that screening mammography does reduce breast cancer mortality. The ... less likely to die of breast cancer than women who ... that women in a screened population are 30 percent more ...
... provide a scientific basis for eventual treatment, neurology researchers ... of a protein that// helps keep brain activity in ... to be an underlying reason for seizures and memory ... brain injury (TBI). ,“A traumatic brain injury ...
Cached Medicine News:Health News:Flaws Reported in overview of US organ transplants 2Health News:Now, Silica Nanobubbles for Targeted Drug Delivery 2Health News:Genomic tests for better cancer treatment 2Health News:Portion Sizes in Restaurants Larger than Before 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 2Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 3Health News:Mammograms Reduce Breast Cancer Deaths, But Increase Overdiagnosis 4Health News:How Brain Injury Leads to Seizures, Memory Problems 2
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
... Adapter in conjunction with the Vortex Genie 2 ... Mo Bio Vortex Adapter is an inexpensive alternative ... which offer the same technology. This particular ... one time and will fit any Vortex Genie ...
... V-500 with Vacuum Controller V-800 and water-cooled secondary ... Compact Housing Model V-500 ... to handle most vacuum applications. Applications ... two rotary evaporators Laboratory vacuum source ...
Medicine Products: